Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza
While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.
You may also be interested in...
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.